Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)

Introduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/c...

Descripción completa

Detalles Bibliográficos
Autores: Machuca, I., Domínguez, A., Amaya, R., Arjona, C., Gracia-Ahufinger, I., Carralon, M., Giron, R., Gea, I., Benito, Natividad|||0000-0001-6410-013X, Martin, A., Galan, F., Martinez, Jose Antonio, Iglesias, R., Revuelto, J., Caston, J.J., Cano, Amanda|||0000-0001-9567-4283, Ruiz-Arabi, E., Martínez-Martínez, L., Torre-Cisneros, J.|||0000-0003-1529-6302
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:320042
Acceso en línea:https://ddd.uab.cat/record/320042
https://dx.doi.org/urn:doi:10.1007/s40121-024-01077-z
Access Level:acceso abierto
Palabra clave:Pseudomonas aeruginosa
Carbapenem
Cilastatin
Imipenem
Multidrug
Relebactam
Resistant
id ES_e930936edf8b4ab01fb9d4042ad8e7fe
oai_identifier_str oai:ddd.uab.cat:320042
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)Machuca, I.Domínguez, A.Amaya, R.Arjona, C.Gracia-Ahufinger, I.Carralon, M.Giron, R.Gea, I.Benito, Natividad|||0000-0001-6410-013XMartin, A.Galan, F.Martinez, Jose AntonioIglesias, R.Revuelto, J.Caston, J.J.Cano, Amanda|||0000-0001-9567-4283Ruiz-Arabi, E.Martínez-Martínez, L.Torre-Cisneros, J.|||0000-0003-1529-6302Pseudomonas aeruginosaCarbapenemCilastatinImipenemMultidrugRelebactamResistantIntroduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results: The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions: Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.Universitat Autònoma de Barcelona 22025-01-0120252025-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/320042https://dx.doi.org/urn:doi:10.1007/s40121-024-01077-zreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3200422026-06-06T12:50:31Z
dc.title.none.fl_str_mv Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
title Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
spellingShingle Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Machuca, I.
Pseudomonas aeruginosa
Carbapenem
Cilastatin
Imipenem
Multidrug
Relebactam
Resistant
title_short Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
title_full Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
title_fullStr Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
title_full_unstemmed Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
title_sort Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
dc.creator.none.fl_str_mv Machuca, I.
Domínguez, A.
Amaya, R.
Arjona, C.
Gracia-Ahufinger, I.
Carralon, M.
Giron, R.
Gea, I.
Benito, Natividad|||0000-0001-6410-013X
Martin, A.
Galan, F.
Martinez, Jose Antonio
Iglesias, R.
Revuelto, J.
Caston, J.J.
Cano, Amanda|||0000-0001-9567-4283
Ruiz-Arabi, E.
Martínez-Martínez, L.
Torre-Cisneros, J.|||0000-0003-1529-6302
author Machuca, I.
author_facet Machuca, I.
Domínguez, A.
Amaya, R.
Arjona, C.
Gracia-Ahufinger, I.
Carralon, M.
Giron, R.
Gea, I.
Benito, Natividad|||0000-0001-6410-013X
Martin, A.
Galan, F.
Martinez, Jose Antonio
Iglesias, R.
Revuelto, J.
Caston, J.J.
Cano, Amanda|||0000-0001-9567-4283
Ruiz-Arabi, E.
Martínez-Martínez, L.
Torre-Cisneros, J.|||0000-0003-1529-6302
author_role author
author2 Domínguez, A.
Amaya, R.
Arjona, C.
Gracia-Ahufinger, I.
Carralon, M.
Giron, R.
Gea, I.
Benito, Natividad|||0000-0001-6410-013X
Martin, A.
Galan, F.
Martinez, Jose Antonio
Iglesias, R.
Revuelto, J.
Caston, J.J.
Cano, Amanda|||0000-0001-9567-4283
Ruiz-Arabi, E.
Martínez-Martínez, L.
Torre-Cisneros, J.|||0000-0003-1529-6302
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Pseudomonas aeruginosa
Carbapenem
Cilastatin
Imipenem
Multidrug
Relebactam
Resistant
topic Pseudomonas aeruginosa
Carbapenem
Cilastatin
Imipenem
Multidrug
Relebactam
Resistant
description Introduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results: The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions: Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.
publishDate 2025
dc.date.none.fl_str_mv 2
2025-01-01
2025
2025-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/320042
https://dx.doi.org/urn:doi:10.1007/s40121-024-01077-z
url https://ddd.uab.cat/record/320042
https://dx.doi.org/urn:doi:10.1007/s40121-024-01077-z
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423006329077760
score 15,812455

Similares en LA Referencia